| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Tango Therapeutics, Inc.
13D/A
TNGX · 87583X109
|
4.7% |
2/10/2026
Event 2/6/2026
|
||||
| Third Rock Ventures IV, L.P. | 4.7% | |||||
| Third Rock Ventures GP IV, L.P. | 4.7% | |||||
| TRV GP IV, LLC | 4.7% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Maze Therapeutics, Inc.
13G/A
MAZE · 578784100
|
9.3% |
2/13/2026
Event 12/31/2025
|
||||
| Third Rock Ventures IV, L.P. | 9.3% | |||||
| Third Rock Ventures GP IV, L.P. | 9.3% | |||||
| TRV GP IV, LLC | 9.3% | |||||
| Third Rock Ventures V, L.P. | 2.0% | |||||
| Third Rock Ventures GP V, L.P. | 2.0% | |||||
| TRV GP V, LLC | 2.0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.